Medpace Holdings, Inc.
NASDAQStock trades at $622.11 after 1% one-day gain. Analyst Kevin Caliendo's call marks a shift from Sell rating. Consensus sits at Hold with mean target of $588.85, implying modest downside. CEO August Troendle has sold $178M in shares over 90 days; latest dump of 27,833 shares on Sept 24 at $621.33. Short interest at 5.9% of float; cost to borrow minimal at 0.32%. Next earnings Oct 19.
MEDP UBS upgrades to neutral, raises price target 66% to $673 from $405.
Stock trades at $622.11 after 1% one-day gain. Analyst Kevin Caliendo's call marks a shift from Sell rating. Consensus sits at Hold with mean target of $588.85, implying modest downside. CEO August Troendle has sold $178M in shares over 90 days; latest dump of 27,833 shares on Sept 24 at $621.33. Short interest at 5.9% of float; cost to borrow minimal at 0.32%. Next earnings Oct 19.
Snapshot as of 7 Oct 2026
Medpace Holdings heads into its October 19 earnings with analyst sentiment firming while the CEO's open-market selling runs uninterrupted, a divergence that has widened since the last note. The Street moved clearly in…
Medpace Holdings heads into its October 19 earnings with a striking divergence at the top: the CEO is selling heavily in the open market while the Street's most recent analyst move is a bullish upgrade. The insider…
Medpace Holdings heads into the final week of August with a striking divergence: the stock is up 4% on the week, but insiders are selling aggressively and options traders have swung sharply toward put protection. The…
Medpace Holdings enters the back half of August with a clear tension: the stock just delivered one of its best earnings reactions in recent memory, yet the founder-CEO has been selling steadily since the results…
Medpace Holdings reports its second-quarter results on July 23 against a backdrop of unwinding bearish conviction, yet a freshly divided analyst community that has turned more cautious on valuation just as the stock…
Medpace Holdings heads into its July 22 earnings print with the Street turning more cautious just days before results — and two back-to-back downgrades in two days are the defining story this week. The analyst moves…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for MEDP — free to start on ORTEX.
Sign up for free →Open MEDP on ORTEX